In a recent Summary from Expert consensus on effectiveness and safety of DPP4 inhibitors in the treatment of patients with diabetes and COVID-19 [159], it was concluded that the use of the inhibitors may present a specific benefit in reducing mortality, particularly in in-hospital use, reducing admission to intensive care units and the need for mechanical ventilation and most importantly, the use of DPP4 inhibitors appears to be safe in patients with COVID-19. Here, DPP4 is linked to COVID-19.